Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer

BACKGROUND: Everolimus is a mTOR inhibitor used for the treatment of different solid malignancies. Many patients treated with the registered fixed 10 mg dose once daily are in need of dose interruptions, reductions or treatment discontinuation due to severe adverse events. This study determined the...

Descripción completa

Detalles Bibliográficos
Autores principales: de Wit, D., Schneider, T. C., Moes, D. J. A. R., Roozen, C. F. M., den Hartigh, J., Gelderblom, H., Guchelaar, H. J., van der Hoeven, J. J., Links, T. P., Kapiteijn, E., van Erp, N. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921118/
https://www.ncbi.nlm.nih.gov/pubmed/27169792
http://dx.doi.org/10.1007/s00280-016-3050-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921118/
https://www.ncbi.nlm.nih.gov/pubmed/27169792
http://dx.doi.org/10.1007/s00280-016-3050-6

Ejemplares similares